StockNews.com Initiates Coverage on Cutera (NASDAQ:CUTR)

Equities research analysts at StockNews.com began coverage on shares of Cutera (NASDAQ:CUTR) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the medical device company’s stock.

A number of other equities analysts have also recently issued reports on the stock. Stephens lowered their price objective on shares of Cutera from $10.00 to $5.00 and set an “overweight” rating for the company in a research report on Friday, August 9th. Piper Sandler reiterated a “neutral” rating and set a $1.00 price target (down from $3.00) on shares of Cutera in a report on Friday, August 9th.

Cutera Stock Performance

Shares of CUTR stock opened at $0.33 on Tuesday. Cutera has a fifty-two week low of $0.28 and a fifty-two week high of $4.97. The stock’s fifty day moving average price is $0.61 and its two-hundred day moving average price is $1.15. The company has a market cap of $6.57 million, a PE ratio of -0.05 and a beta of 1.35.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CUTR. Bayesian Capital Management LP bought a new stake in Cutera during the 1st quarter worth approximately $33,000. Ground Swell Capital LLC acquired a new position in shares of Cutera during the second quarter worth $37,000. Squarepoint Ops LLC grew its stake in shares of Cutera by 164.5% in the second quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock worth $172,000 after purchasing an additional 70,870 shares during the last quarter. Finally, Bank of Montreal Can increased its holdings in Cutera by 14.2% in the second quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock valued at $455,000 after purchasing an additional 35,248 shares during the period. Institutional investors and hedge funds own 90.70% of the company’s stock.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.